menu
    • menu

    Company profile for Arcus Biosciences

    NEW Drugs in Dev: 10
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Arcus is an oncology-focused biopharmaceutical company leveraging its deep cross-discipline expertise to discover highly differentiated therapies and develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus’s lead small molecule programs target the adenosine axis, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Arcus BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3928 Point Eden Way Hayward, CA 94545
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://arcusbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Arcus Biosciences Unveils Q1 2026 Financials And Pipeline
    Arcus Biosciences Unveils Q1 2026 Financials And Pipeline

    05 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-05/arcus-biosciences-reports-first-quarter-2026-financial-results-and-provides-a-pipeline-update

    PHARMIWEB
    05 May 2026
    Share Share
    Arcus Biosciences Announces New Employment Inducement Grants
    Arcus Biosciences Announces New Employment Inducement Grants

    24 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260424182979/en/Arcus-Biosciences-Announces-New-Employment-Inducement-Grants

    BUSINESSWIRE
    24 Apr 2026
    Share Share
    Gilead Loosens Ties To Arcus As TIGIT Dream Ends In Ph. 3 Fail
    Gilead Loosens Ties To Arcus As TIGIT Dream Ends In Ph. 3 Fail

    21 Apr 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/gilead-loosens-ties-arcus-after-tigit-dream-finally-ends-phase-3-failure

    FIERCE BIOTECH
    21 Apr 2026
    Share Share
    Arcus Biosciences to Host Q1 2026 Earnings and Pipeline Call
    Arcus Biosciences to Host Q1 2026 Earnings and Pipeline Call

    21 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260421797522/en/Arcus-Biosciences-to-Host-Conference-Call-to-Discuss-First-Quarter-2026-Financial-Results-and-Pipeline-Updates

    BUSINESSWIRE
    21 Apr 2026
    Share Share
    Gilead declines another Arcus option after Phase 3 TIGIT fail
    Gilead declines another Arcus option after Phase 3 TIGIT fail

    20 Apr 2026

    // ENDPOINTS

    https://endpoints.news/gilead-declines-another-arcus-option-after-phase-3-tigit-fail/

    ENDPOINTS
    20 Apr 2026
    Share Share
    Arcus Biosciences Unveils 2025 Financials And Pipeline Update
    Arcus Biosciences Unveils 2025 Financials And Pipeline Update

    25 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260225014331/en/Arcus-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-a-Pipeline-Update

    BUSINESSWIRE
    25 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search